Toronto - Delayed Quote CAD

Appili Therapeutics Inc. (APLI.TO)

0.0300
-0.0050
(-14.29%)
At close: May 9 at 2:33:05 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for APLI.TO

Recent News: APLI.TO

View More
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
GlobeNewswire 8 days ago
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™

Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
GlobeNewswire 11 days ago
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
GlobeNewswire last month
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
GlobeNewswire last month

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
Business Wire 4 months ago
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
GlobeNewswire 5 months ago
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
GlobeNewswire 5 months ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
Business Wire 5 months ago

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
Business Wire 5 months ago
Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders
GlobeNewswire 5 months ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
Business Wire 5 months ago
View More

Related Tickers

BETR.CN BetterLife Pharma Inc.
0.0850
-10.53%
 
LOBE.CN Lobe Sciences Ltd.
0.0250
0.00%
 
MSCL.TO Satellos Bioscience Inc.
0.6600
+1.54%
 
MSCLF Satellos Bioscience Inc.
0.4820
0.00%
 
ENGN enGene Holdings Inc.
2.9600
-12.68%
 
CSCI COSCIENS Biopharma Inc.
3.5500
+7.25%
 
MBX.TO Microbix Biosystems Inc.
0.3600
+2.86%
 
STTK Shattuck Labs, Inc.
0.9479
+0.88%
 
ADTX Aditxt, Inc.
1.7300
+1.76%
 
INDP Indaptus Therapeutics, Inc.
0.4006
-0.62%